InDex Pharmaceuticals Holding AB today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office.
The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
The patent, entitled Method for prevention of colectomy (patent number 9492516), was filed in 2012 and will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.
‘This patent further strengthens and extends our intellectual property position for cobitolimod in the US, which is the most important pharmaceutical market in the world,’ said Peter Zerhouni, CEO of InDex Pharmaceuticals. ‘We are pleased that the USPTO confirms that cobitolimod is a unique and innovative asset for the treatment of refractory ulcerative colitis.’
The USPTO has notified the company that the patent will be granted on November 15, 2016. Corresponding patent applications have also been filed in Europe, Japan and Canada and are being diligently prosecuted to grant.